Scout Investments Inc. Sells 1,134 Shares of Balchem Co. (NASDAQ:BCPC)

Scout Investments Inc. trimmed its stake in Balchem Co. (NASDAQ:BCPCFree Report) by 1.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,917 shares of the basic materials company’s stock after selling 1,134 shares during the period. Scout Investments Inc. owned 0.23% of Balchem worth $10,846,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its position in shares of Balchem by 0.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,083,212 shares of the basic materials company’s stock worth $161,128,000 after acquiring an additional 6,885 shares in the last quarter. Geneva Capital Management LLC increased its position in Balchem by 0.5% during the 4th quarter. Geneva Capital Management LLC now owns 767,211 shares of the basic materials company’s stock valued at $114,123,000 after buying an additional 3,885 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Balchem by 1.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 687,485 shares of the basic materials company’s stock valued at $102,265,000 after buying an additional 11,629 shares in the last quarter. Clearbridge Investments LLC increased its position in Balchem by 0.5% during the 4th quarter. Clearbridge Investments LLC now owns 521,590 shares of the basic materials company’s stock valued at $77,587,000 after buying an additional 2,801 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in Balchem by 9.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 402,621 shares of the basic materials company’s stock valued at $49,941,000 after buying an additional 36,011 shares in the last quarter. 87.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on BCPC shares. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. HC Wainwright increased their price objective on Balchem from $167.00 to $170.00 and gave the company a “buy” rating in a report on Monday, May 6th.

Get Our Latest Stock Analysis on BCPC

Balchem Stock Performance

Shares of BCPC stock traded down $1.58 during mid-day trading on Friday, reaching $152.25. The stock had a trading volume of 57,727 shares, compared to its average volume of 78,665. The business’s fifty day moving average is $150.27 and its 200-day moving average is $146.34. The company has a current ratio of 2.61, a quick ratio of 1.72 and a debt-to-equity ratio of 0.30. The firm has a market cap of $4.94 billion, a price-to-earnings ratio of 43.01, a PEG ratio of 3.63 and a beta of 0.70. Balchem Co. has a 1-year low of $110.74 and a 1-year high of $159.52.

Balchem (NASDAQ:BCPCGet Free Report) last announced its quarterly earnings data on Friday, May 3rd. The basic materials company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $239.66 million during the quarter, compared to analyst estimates of $234.12 million. Balchem had a net margin of 12.35% and a return on equity of 11.03%. On average, research analysts forecast that Balchem Co. will post 3.86 earnings per share for the current year.

Insider Activity

In other news, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total value of $764,900.00. Following the sale, the director now owns 9,009 shares in the company, valued at $1,378,196.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total value of $764,900.00. Following the sale, the director now owns 9,009 shares in the company, valued at $1,378,196.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael Robert Sestrick sold 1,929 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $154.45, for a total value of $297,934.05. Following the completion of the sale, the senior vice president now owns 4,878 shares in the company, valued at approximately $753,407.10. The disclosure for this sale can be found here. Corporate insiders own 1.25% of the company’s stock.

Balchem Profile

(Free Report)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

Featured Articles

Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPCFree Report).

Institutional Ownership by Quarter for Balchem (NASDAQ:BCPC)

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.